ClinicalTrials.Veeva

Menu
O

Oncocentro | Vina Del Mar, Chile

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
MK-7902
Enzalutamide
Deucravacitinib
Cemiplimab
Lenvatinib
Fianlimab
Androgen
MK-3475-826
MK-7339

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 16 total trials

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)
Locations recently updated

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Other: Placebo
Drug: Deucravacitinib

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling
Melanoma
Drug: Cemiplimab
Drug: Placebo

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalut...

Active, not recruiting
Metastatic Hormone-Sensitive Prostate Cancer
Drug: Androgen Deprivation Therapy (ADT)
Other: Placebo

The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.

Enrolling
Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Drug: ABP 234
Drug: Pembrolizumab

This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-...

Active, not recruiting
Melanoma
Other: Placebo
Biological: Pembrolizumab

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have...

Active, not recruiting
Renal Cell Carcinoma
Drug: Placebo
Biological: Pembrolizumab

The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvat...

Active, not recruiting
Nonsquamous Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Placebo matching lenvatinib

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurre...

Active, not recruiting
Uterine Cervical Neoplasms
Drug: Cisplatin
Biological: Pembrolizumab

The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel\* PLUS pembrolizumab (MK-3475) and maintenanc...

Active, not recruiting
Peritoneal Neoplasms
Fallopian Tube Cancer
Drug: Docetaxel
Drug: Placebo for olaparib

The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after in...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, wit...

Active, not recruiting
Endometrial Neoplasms
Drug: Placebo for pembrolizumab
Drug: Cisplatin

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Biological: Pembrolizumab

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by eit...

Active, not recruiting
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Drug: Cisplatin
Biological: Pembrolizumab

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Amgen logo
Bristol-Myers Squibb (BMS) logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems